1. Thromboembolic event rates differ according to various guideline treatment thresholds and methodological approaches.2. Administration of the latter is also associated with increased risk of venous thromboembolic complications. 3. It can lead to either bleeding or thromboembolic complications, or is clinically without pathological findings. 4. Its main use, therefore, is to exclude thromboembolic disease where the probability is low. 5. Pulmonary thromboendarterectomy ( PTE ) is a surgical procedure that is used for chronic thromboembolic pulmonary hypertension. 6. Studies have demonstrated an increased risk of recurrent venous thromboembolic events in patients with protein C deficiency. 7. Cavitation is also suspected as a contributing factor in blood cell damage and increased risk of thromboembolic complications. 8. From 1965 to 1967 Inman designed and directed studies on the role of oral contraceptives in thromboembolic disease. 9. In chronic thromboembolic pulmonary hypertension patients, Ral GTPases have been observed to be highly active in their platelets. 10. In the clinic, heparin is administered as an anticoagulant and is also the first line choice for thromboembolic diseases.
Mobile